Lightcalls.com
 

greatest in number famous because i...

greatest in number famous because it is an antioxidant that is one as well as the other fat- and water-soluble, alpha-lipoic acid, or ALA, is a vitamin-like nutrient that is able to inactivate unrestrained radical toxins in our muscles, internal organs, fatty tissues and brain. Besides being a grand antioxidant itself, ALA recycles worn-out vitamin C vitamin E and glutathione, and makes them useful again.

In addition, ALA helps small rooms to convert food into capacity of work by improving the breakdown of sugar. A 2-year of long date climbing the walls after an evening meal, brings very large amounts of ALA in his liver, while a 60-year-old man after the same meal can be plant asleep on the couch; he does not synthesize earnestly ALA and must get it from one side supplementation.

My experience with alpha-lipoic acid

I first became familiar with the clinical use of alpha-lipoic acid when I was an internal medicine resident in 1977 couple "incurable" liver disease patients were assigned to my care and the senior doctors said they were hopeles Because I was training to be a medical doctor, I was reckon uponed to follow the suggestions of the chiefs and just support the patients medically. However, because of my PhD education (Doctor of Philosophy), I sought recent ways to reverse their "hopeless" conditions.



I called with Fred Barter, M.D., Chief of Endocrinology at the National Institutes of Health, to ask him if he knew of any modern promising therapy for liver disease. Barter said that, in Prague, favorable eventuates were obtained with thioctic acid (another name for AKA). He sent me a package of AkA that day, and I administered it to the liver patients. To my astonishment, they entirely recovered within 2 weeks. I am still in touch with these patients and they do not have any residual liver damage, 23 years later. My supervisors were not impressed and told me that in united case in a million, there is a spontaneous remission, and this time there were two

The nearest week, another couple with "terminal" liver disease was assigned to my service. They had been poisoned by means of the most toxic liver destruction agents, Amanita virosa or "Death Cap" mushroom. I was told that I could not use ALA since it had not been sufficiently studied in the U This time, I arrived at the patient's field fully prepared to follow the orders of the senior doctors. if it be not that when I saw how young the patients were, I ordered the ALA and administered it to them. They reclaimed quickly. Over the past 23 years, I have used ALA to treat liver disease including hepatitis C diabetes mellitus complications and other serious disorders, with the same extraordinarily advantageous results.

Alpha lipoic acid is surpassingly effective. Researchers have reported that ALA can inhibit viral replication, interrupt cataracts, increase the sensitivity of your small rooms to both glucose and insulin (reversing "syndrome X" and preventing diabetes) and defend your skin and internal organs from damaging radiation.

In 1980 Barter and I published sum of two units papers describing our success with ALA for accurate liver disease using the NIH protocol and the research was widely accepted in Germany. Today, ALA is an important medicine in Europe and is available as a nutritional postscript in the U.S. If you have a condition that you think might be effectively treated with ALA, find a health professional who understands the correct use of this supplement.

REFERENCES

Baur, A., Harrer, T et al. "Alpha-lipoic acid is an effective inhibitor of human immunodeficiency virus replication," Klinische Wochenschrift 69:722-724 1991

Berkson, BM "A Conservative Triple Antioxidant Approach to the Treatment of Hepatitis C" Medizinische Klinik (The Official German Journal of Internal Medicine), 94 (Supplement III): 84-89 1999

Berkson, B The Alpha-Lipoic Acid Breakthrough. Rocklin, CA: Prima Publishing, 1998

Burket V Koike, T et al. "Dihydrolipoic acid covers pancreatic islet cells from inflammatory attack," Agents and Actions 38;60-65 1993

Jacob, s Henriksen, EJ, et al. "Enhancement of grape-sugar disposal in patients with protoplast 2 diabetes by alpha-lipoic acid," Arzneimittelforschung 45:872-874 1995

Prehn J Karkoutly C et al. "Dihydrolipoic acid shapes neuronal injury after cerebral ischemia," Journal of Cerebral relations Flow and Metabolism 12:78-87, 1992

Burt Berkson, MD PhD practices integrative medicine and is involved in various research programs in small cavity biology and mycology. He is President of the Integrative Medical Center of of recent origin Mexico, and has worked as a professor for fresh Mexico State University. Dr. Berkson is the author of AU About B Vitamins and The Alpha Lipoic Acid Breakthrough.

COPYRIGHT 2000 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved

COPYRIGHT 2000 Gale Group



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.